XOMA Royalty Announces Closing of Its Acquisition by Ligand

XOMA Royalty Corporation said Ligand Pharmaceuticals (Nasdaq: LGND) has completed its previously announced acquisition of XOMA Royalty. The article provides no deal value or financial guidance changes, so near-term impact is likely limited and more event-driven than fundamental.

Analysis

XOMA Royalty Corporation said Ligand Pharmaceuticals (Nasdaq: LGND) has completed its previously announced acquisition of XOMA Royalty. The article provides no deal value or financial guidance changes, so near-term impact is likely limited and more event-driven than fundamental.